131 / 242
131
PROPOFOL AND REMIFENTANIL SEDATION FOR BRONCHIAL THERMOPLASTY
10
Table 1.
Baseline characteristics
Subjects, n
13
Bronchial Thermoplasty procedures, n
32
Gender, male/female
2/11
Age, years
42 ± 14
Pre-bronchodilator FEV1, % predicted
78 ± 26
Inhaled corticosteroids of futicasone or equivalent, μg/day
1,269 ± 525
Inhaled LABA of salmeterol or equivalent, μg/day
154 ± 97
Chronic oral corticosteroid use, n
6
Oral corticosteroids of prednisone or equivalent, mg/day
13 ± 7
Values are means ± standard deviations unless otherwise indicated. FEV1, forced expiratory volume in 1s; LABA,
long-acting β
2
agonist.
Primary endpoints
The median VAS scores assessed by the patients were: overall satisfaction 9.5 (IQR 8.5–
10.0) (Figure 1), dyspnea 0.0 (IQR 0.0–0.6), pain 0.1 (IQR 0.0–1.0), cough 0.5 (IQR 0.0–2.1),
and anxiety 0.1 (IQR 0.0–0.7) (Figure 2a; Table 2). The mean VAS scores assessed by the
bronchoscopists were: overall patient cooperation 9.1 (IQR 8.5–9.6) (Figure 1), dyspnea 0.3
(IQR 0.0–0.9), pain 0.2 (IQR 0.0–1.3), cough 1.2 (IQR 0.7–2.0), and discomfort 0.6 (IQR 0.3–1.5)
(Figure 2b; Table 2). All patients were willing to undergo the BT procedures under the same
conditions again and would recommend this form of sedation to their best friend (Table 2).
Figure 1.
Patients’ and bronchoscopists’ median VAS score for overall procedural satisfaction and
overall patient cooperation